FDA's Green Flag to Ascendis's Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone Deficiency
For the treatment of growth failure due to deficiency of growth hormones, the USFDA approved Ascendis Pharma's Skytrofa (lonapegsomatropin-tcgd) for children of one year and older suffering from an improper secretion of endogenous growth hormone (GH). Growth Hormone Deficiency, commonly known as dwarfism, can constitute short stature and complications with metabolism, which arise due to inadequate production of growth hormones by the pituitary gland inside the body.
This approval became Denmark-based pharmaceutical's first FDA approval beating rival drugs fro...
